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Adrenal medullary hyperplasias (AMHs) are adrenal medullary proliferations with a size b1 cm, while larger lesions
are considered as pheochromocytoma (PCC). This arbitrary distinction has been proposed decades ago, although
the biological relationship between AMH and PCC has never been investigated. Both lesions are frequently
diagnosed in multiple endocrine neoplasia type 2 (MEN2) patients in whom they are considered as two unrelated
clinical entities. In this study, we investigated the molecular relationship between AMH and PCC in MEN2 patients.
Molecular aberrations of 19 AMHs and 13 PCCs from 18 MEN2 patients were determined by rearranged during
transfection (RET) proto-oncogene mutation analysis and loss of heterozygosity (LOH) analysis for chromosomal
regions 1p13, 1p36, 3p, and 3q, genomic areas covering commonly altered regions in RET-related PCC. Identical
molecular aberrations were found in all AMHs and PCCs, at similar frequencies. LOH was seen for chromosomes
1p13 in 8 of 18 (44%), 1p36 in 9 of 15 (60%), 3p12-13 in 12 of 18 (67%), and 3q23-24 in 10 of 16 (63%) of AMHs,
and for chromosome 1p13 in 13 of 13 (100%), 1p36 in 7 of 11 (64%), 3p12-13 in 4 of 11 (36%), and 3q23-24 in 11
of 12 (92%) of PCCs. Our results indicate that AMHs are not hyperplasias and, in clinical practice, should be
regarded as PCCs, which has an impact on diagnosis and treatment of MEN2 patients. We therefore propose to
replace the term AMH by micro-PCC to indicate adrenal medullary proliferations of less than 1 cm.
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Table 1. Clinical and Tumor Data of 32 Tumors from 18 Patients with MEN2.
Pt Family M/F m/b Age Mutation RET L (cm) R (cm) MTC PHP
1 A F b 20 pCys 634 Arg 7 0.4 + −
2 A M b 55 pCys 634 Arg 0.7 – + +
3 B F b 32 pCys 634 Arg – 0.7 + +
4 B M b 42 pCys 634 Arg 0.6 0.4 + +
5 B F b 18 pCys 634 Arg 0.2 0.7 + +
6 B F b 24 pCys 634 Arg 0.9 0.7 + −
7 B F b 50 pCys 620 Arg b1 b1 + −
8 C F b 52 pCys 634 Arg 2 0.8 + −
9 C F b 38 pCys 634 Arg 4 1.6 + +
10 C F b 38 pCys 634 Arg 0.8 – + −
11 C F b 51 pCys 634 Arg 0.9 4 + +
12 D F b 29 pCys 634 Arg 4 0.8 + +
13 E F b 29 pCys 634 Arg 5 3 + −
14 F M b 26 pCys 611 Tyr 0.8 3 + +
15 G M b 23 pMet 918 Thr 2.5 0.6 + −
16 H F b 51 pCys 634 Arg – 1.5 + −
17 I F b 34 pCys 634 Arg 0.2 0.8 + −
18 J F b 25 pCys 634 Arg 4.2 2 + +
Pt, patient; M/F, male/female; m/b, malignant/benign; Age, years; L, tumor size in left adrenal
gland; R, tumor size in right adrenal gland; MTC, medullary thyroid carcinoma; PHP, primary
hyperparathyroidism.
Neoplasia Vol. 16, No. 10, 2014 Adrenal medullary hyperplasia Korpershoek et al. 869Introduction
Pheochromocytomas (PCCs) are tumors that originate from adrenal
medulla chromaffin cells and occur with an incidence of 1 to 2 per
100,000. PCCs are generally benign and only 10% of cases is
metastatic. The clinical impact of PCCs is far beyond the issue of
malignancy since the majority of PCCs produce catecholamines,
which can cause severe life-threatening situations such as myocardial
infarctions and cerebrovascular accidents [1]. Up to 25% of PCCs
occur in the context of hereditary cancer syndromes. These include
multiple endocrine neoplasia type 2 (MEN2) caused by germ-line
activating rearranged during transfection (RET) proto-oncogene
mutations, von Hippel-Lindau disease due to inactivating von Hippel-
Lindau gene mutations, neurofibromatosis type 1 as a result of neuro-
fibromatosis type 1 gene inactivation, and the PCC-paraganglioma
syndrome resulting from inactivation of the succinate dehydrogenase-A,
-B -C, -D, or -AF2 genes [2–4]. Other genes that have recently been
associated with inherited PCCs are TMEM127, KIF1B, PHD2,MAX,
HIF2a, and FH [5–10]. In total, mutations in all genes described above
account for more than 50% of the PCCs and paragangliomas, the latter
being tumors of chromaffin cells that arise outside the adrenal gland
and, if located in the thorax or abdomen, generally also produce
catecholamines [11].
Most syndrome-related PCCs are associated with RET mutations,
which cause the autosomal dominant MEN2 syndrome. Fifty percent
of patients with MEN2 develop PCC, which in up to 80% of patients
occur bilaterally. Half of the bilateral lesions are diagnosed
synchronously, but contralateral PCC can occur after an interval of
many years [12]. The RET proto-oncogene encodes a transmembrane
receptor tyrosine kinase involved in regulation of cell proliferation
and apoptosis. Activating mutations in RET transform this proto-
oncogene into an oncogene with constitutive activation of the
receptor as a result. The activating germ-line mutation in the RET
gene in patients with MEN2 is a prerequisite though insufficient to
develop PCC and additional somatic molecular aberrations have to
occur in adrenal medullary cells to initiate PCC development [13,14].
Some patients withMEN2 present with adrenal medullary hyperplasia
(AMH), which is considered as a benign generally non–catecholamine-
overproducing lesion. In contrast, PCCs are usually characterized by
catecholamine overproduction and are potentially malignant. The
distinction between AMH and PCC is currently based on the diameter
of the lesion: An AMH is defined as a nodular and/or diffuse lesion of the
adrenal medulla with a size of maximally 1 cm in diameter, whereas a
larger lesion is considered as a PCC [1,15,16]. This definition has been
put forward more than three decades ago by Carney et al. [17] and has
been adopted by the Armed Forces Institute of Pathology [18].
By definition, a hyperplasia is a non-neoplastic lesion with an
increased number of normal cells in normal arrangement in an organ
or tissue, while a PCC is a neoplastic lesion composed of cancer cells.
Most AMH cases are found in known hereditary PCC syndrome
patients as a result of surveillance. Non-hereditary AMH is extremely
rare and generally only diagnosed after catecholaminergic symptoms
mimicking PCC [1,19–21].
Early genetic aberrations that occur in sporadic as well as in hereditary
PCC, especially in MEN2, include loss of chromosomal arms 1p (82-
100%), 3p (24-31%), and 3q (41-52%) [22–24]. The high frequencies
of these chromosomal aberrations indicate that they might be causally
related to PCC tumorigenesis, but tumor suppressor genes on these
chromosomes are yet still to be found. In addition, allelic imbalance of
the RET gene, in favor of the mutant allele, has been described inMEN2-related neoplasia [25]. Currently, PCCandAMHare considered
as two different clinical entities and their distinction is based on the
lesional size. However, molecular evidence for this clinical distinction of
AMH and PCC is lacking since data on molecular aberrations in AMH
have not been reported to date. In the present study, we investigated the
biologic relationship between AMHand PCCby determiningmolecular
abnormalities in these lesions. Hence, 32 adrenal lesions (19 AMHs and
13 PCCs) from 18 patients with MEN2 were investigated for loss of
chromosomes 1p13, 1p36, 3p, and 3q by loss of heterozygosity (LOH)
analysis using highly polymorphic microsatellite markers. In addition,




For several decades, at the Erasmus MC, the therapy of choice for
MEN2 patients with elevated catecholamine levels has been bilateral
adrenalectomy. In the resected adrenals, nodular and/or diffusemedullary
lesions of variable size were found. The generally used size criterion of 1
cm, put forward by Carney et al. [17] and described in the Armed Forces
Institute of Pathology guidelines [18], was used in the differential
diagnosis of AMH and PCC.
Thirty-two histologically proven adrenal medullary lesions were
investigated, comprising 19 AMHs and 13 PCCs, from 18 patients
from 10 differentMEN2 families, all with a known germ-lineRET gene
mutation (Table 1). Of the 18 patients, 14 underwent bilateral and 4
underwent unilateral adrenalectomy. All adrenal tumors were benign
and were collected between 1982 and 2005. The routine formalin-fixed
and paraffin-embedded tissue specimens were retrieved from the files
of the Department of Pathology, Erasmus MC, following approval of
the experimental design and protocols by the Institutional Medical
Ethics Committee.
From each case, lesional and normal DNAwas isolated from formalin-
fixed and paraffin-embedded tissues by manual microdissection of tissue
fragments comprising more than 80% lesional cells and 100% normal
cells, respectively (Supplementary Figure 1). The isolated tissue fragments
were digested by standard detergent–proteinase K treatment and DNA
Table 2. Microsatellite Markers, Chromosomal Localization, Primer Sequences, and Approximate Product Sizes of the Eight Markers in Four Regions.
Marker Localization Forward 5′→3′ Reverse 5′→3′ Size (bp)
1 D1S252 1p13.1 AGCTTTTTACTCTTAACCTATTCAT TCATTAATACACATGTTCTCTGC 107
2 D1S2881 1p13.2 ATCTGCCAGCCCATGA CAAACAGAGCCTGGCA 188
3 D1S2885 1p36.11 ATCTGCCAGCCCATGA CAAACAGAGCCTGGCA 127
4 D1S234 1p36.11 GCCCAGGAGGTTGAGG CTGTAATTCAAGCCTGCCTT 142
5 D3S3681 3p12.3 GTGAGAACCATTTGGGGCAG CCCTGACAGATAGCTCGCC 226
6 D3S3551 3p13 AACGGAGTTCCCACATAAA CTTTTGTCTGTATTGCTAATGAACC 142
7 D3S3694 3q23 AGTGTCCATCAACATGGG GAATCCTGTTATTTGTGCGA 162
8 D3S1569 3q24 GCACCTTGGCTTACCTTCTA CTTTAAGAACCTTTCAACTGTCC 234
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tion. Relevant characteristics and clinical data are summarized in Table 1.
LOH Analysis
All DNA samples were analyzed for allelic imbalances of
chromosomes 1p13, 1p36, 3p, and 3q using highly polymorphic
microsatellite markers, as summarized in Table 2. Polymerase chain
reaction (PCR) amplification of paired lesional and normal DNA was
performed in reaction mixtures of 15 μl. Each reaction contained 50
to 100 ng of template DNA, 0.02 mM dATP, 0.2 mM dTTP,
dGTP, dCTP each, 0.8 μCi α32P-dATP, 20 pmol of each primer,
1.5 mM MgCl2, 10 mM Tris-HCl, 50 mM KCl, and 1 unit of Taq
DNA polymerase (Amplitaq Gold; PerkinElmer, Norwalk, CT). An
initial denaturation step at 94°C for 5 minutes was followed by 35
cycles of denaturation at 94°C for 45 seconds, annealing at 55°C for
60 seconds, and extension at 72°C for 60 seconds. A final extension
step was carried out at 72°C for 10 minutes. PCR products of tumor
and normal DNA from each patient were diluted 1:1 in 10 μl of
loading buffer (95% formamide, 20 mM EDTA, 0.05% xylene
cyanol, 0.05% bromophenol blue) and loaded onto a denaturing 6%
polyacrylamide gel. Electrophoresis was carried out at 60 W for 90
minutes. The gels were dried and exposed to X-ray film overnight at
−80°C. Results were scored by two independent investigators. In
addition, part of the LOH markers was investigated by PCR with
fluorescence-labeled primers (Invitrogen, Paisley, United Kingdom)
for 28 cycles with an annealing temperature of 60°C, and amplified
products were analyzed, along with LIZ 500 size standard (Applied
Biosystems, Foster City, CA), using capillary electrophoresis on an
ABI 3130-XL genetic analyzer (Applied Biosystems).
RET Gene Allelic Imbalance Analysis
From eight PCCs and eight AMHs, tumor DNA was investigated
for RET gene allelic imbalance by PCR amplification of tumor and
matched normal DNA fragments containing the RET mutation. The
PCR products were bidirectionally cycle sequenced on an ABI 3130-
XL genetic analyzer (Applied Biosystems). Data were analyzed using
GeneMarker software (SoftGenetics LLC, State College, PA).
Results
Nineteen AMHs and 13 PCCs from 18 patients with MEN2 were
investigated for LOH on chromosomal regions 1p13, 1p36, 3p12-13,
and 3q23-24. In all cases, there was sufficient DNA to perform LOH
analysis on the four different loci with two highly polymorphic markers
per locus. Representative LOH and retention of heterozygosity results
are summarized in Tables 3 and 4. In each of the investigated 19 AMHs
and 13 PCCs, at least one marker demonstrated unequivocal LOH
indicating that the DNA was retrieved from a high percentage of
lesional cells. LOH (of at least one marker per locus) in the AMH cases
was found for 1p13 in 8 of 18 (44%), for 1p36 in 9 of 15 (60%), for3p12-13 in 12 of 18 (67%), and for 3q23-24 in 10 of 16 (63%) of the
informative cases. In the PCCs, LOH was detected at 1p13 in 13 of 13
(100%), 1p36 in 7 of 11 (64%), 3p12-13 in 4 of 11 (36%), and 3q23-24
in 11 of 12 (92%) of informative tumors. From 14 patients, bilateral
lesions were investigated, and in 12 of these cases, the paired proliferations
demonstrated different LOH profiles (example illustrated in Figure 1, left
panel; case 14 different LOH pattern in the bilateral lesions). A total of
128 loci was investigated (4 loci in 32 samples), and only from 14 loci
(1p13 in case 14 L; 1p36 in case 4 L, 4R, 8 L, 8R, 9 L, and 14 L; 3p12-13
in case 1 L, 4R, and 8 L; 3q23-24 in case 1 L, 1R, 17 L, and 17R), no
information on possible LOH could be obtained. The lack of LOH
information from bothmarkers in each of these 14 loci was due to the fact
that the markers were non-informative or no data were obtained.
RET gene allelic imbalance was investigated in 16 tumors by
sequencing of the germ-line RET mutation. In one patient (case 9),
allelic imbalance, in favor of the mutant RET allele, was found in the
bilateral PCCs (Figure 1, right panel).
Discussion
AMHs and PCCs are adrenal medullary non-neoplastic and neoplastic
proliferations, respectively. Both lesions are frequently found in patients
with MEN2, considered unrelated and discriminated by lesional size
(smaller or ≥1 cm, respectively). Because AMHs generally do not
produce catecholamines whereas PCCs do, and PCCs can progress to
malignancy, treatment of AMH and PCC is different. As a result, PCCs
are almost always surgically resected, whereas AMHs are usually only
subjected to follow-up. The diagnostic distinction between AMH and
PCC solely on the basis of the size of the lesion is biologically doubtful
and has been questioned by several researchers [15,16,26]. To obtain
more information on the possible molecular relationship between these
lesions, we investigated MEN2-related AMHs and PCCs.
Genetic abnormalities in PCC have been studied extensively over the
last decades, although understanding of the molecular pathogenesis of
this tumor is still limited. DNA-based analyses, including LOH and
comparative genomic hybridization, have identified several distinct
chromosomal regions frequently lost in PCC, including chromosomes
1p, 3p, and 3q [22–24,27,28]. In particular, loss of 1p has been suggested
to be an early event and occurs at a frequency of 82% to 86% of PCC.
Although chromosomal regions of minimal overlapping loss have been
described at 1p13 and 1p36, relevant tumor suppressor genes have not
been detected to date, which is also the case for regions on chromosomes
3p and 3q [27–29]. In the present study, MEN2-related PCCs and
nodular and/or diffuse AMHs were screened for the presence of
chromosomal aberrations frequently found in MEN2-related and
sporadic PCCs. Frequent LOH at 1p13, 1p36, 3p12, and 3q24 was
found both in the 19 AMH and 13 PCC cases. In addition,
amplification of the mutated RET allele was found in the AMH and
contralateral PCC of one patient (case 12), a molecular aberration
described exclusively in PCCs [25].





Tumor 1p13.1 1p13.2 1p36.11 1p36.11 3p12.3 3p13 3q23 3q24
D1S252 D1S2881 D1S2885 D1S234 D3S3681 D3S3551 D3S3694 D3S1569
1 A L 7.0 PCC n↓ x x NI x NI x
R 0.4 AMHN x x NI n↑ NI x
2 A L 0.7 AMHD n↑ x n↑ n↓ n↑ n↓ n↑
3 B R 0.7 AMHN n↓ n↓ n↓
4 B L 0.6 AMHM n↑ x x x x n↑ x n↑
R 0.4 AMHN n↑ x x x x x x
5 B L 0.2 AMHD NI n↑ n↑ n↓ n↑
R 0.7 AMHD NI n↑
6 B L 0.9 AMHD n↓ n↓ n↓ n↓ NI
R 0.7 AMHD n↓ n↓ n↓ n↓ NI
7 B L u AMHN n↑
R u AMHN n↑
8 C L 2.0 PCC n↑ n↑ x x x x NI n↓
R 0.8 AMHD n↑ x x n↓ NI n↑
9 C L 4.0 PCC n↓ x NI n↓ n↑ n↓
R 1.6 PCC n↓ n↓ NI n↑ n↑ n↓
10 C L 0.8 AMHN NI n↓ n↓ n↑
11 C L 0.9 AMHN n↑ NI n↓
R 4.0 PCC n↓ NI n↑
12 D L 4.0 PCC n↑ x n↑ n↓ n↑ n↓ n↓
R 0.8 AMHN x n↓ n↓ x
13 E L 5.0 PCC NI n↓ x n↑ NI n↓
R 3.0 PCC NI n↓ n↓ n↑ NI n↑ n↑ n↑
14 F L 0.8 AMHM NI x x x NI n↑ x n↓
R 3.0 PCC NI n↑ x NI n↓ n↑
15 G L 2.5 PCC n↓ n↑ n↑ n↑
R 0.6 AMHM n↑ n↓ n↑ n↓ n↓
16 H R 1.5 PCC n↓ n↑ NI
17 I L 0.2 AMHN NI x n↓ NI NI NI
R 0.8 AMHM NI n↓ n↓ NI NI NI
18 J L 4.2 PCC n↓ n↑ NI n↓ n↑ NI
R 2.0 PCC n↑ n↓ NI n↑ n↓ NI
Pt, patient; L, left adrenal gland; R, right adrenal gland; histologic growth patterns: N, nodular; D, diffuse; M, mixed nodular and diffuse.
n↑, Loss of upper allele; n↓, loss of lower allele; NI, not informative; x, no data; u, unknown.
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AMH and PCC. In 12 of 14 bilateral cases, the genomic aberrations
were different in paired lesions indicating that the bilateral lesions are
independent entities. The observed LOH frequencies in PCCs are
comparable to several published series [22–24,27,28]. The percentage
of loss of 1p and 3q is slightly less in the AMH series than in the PCC,
which may be related to the accumulation of genetic abnormalities
during tumor progression in the latter group. However, the
differences are small and they may also be related to chance, which
may be the case for the difference observed for loss of 3p between
AMH (67%) and PCCs (36%).
The current therapy of choice for unilateral catecholamine-
producing PCC patients, including MEN2 patients, is total unilateral
adrenalectomy. In case a contralateral PCC occurs later in life, a
cortex-sparing adrenalectomy is preferred. If a patient presents with
synchronous bilateral PCC, the larger PCC will be resected by total
adrenalectomy and the smaller will be treated by cortex-sparing
adrenalectomy. In general, unilateral cortex-sparing adrenalectomies
are preferred, because of the increased recurrence risk with cortex-Table 4. Overall LOH Results: AMHs versus PCCs.




3q 63 92sparing surgery, while preventing morbidity and mortality due to
adrenocortical insufficiency, occurring in patients with bilateral
adrenalectomy [12,30–32]. Our results indicate that surgical
treatment in patients with MEN2 may need to be more “aggressive”.
In addition to surgical resection of PCCs, AMHs should be
considered for surgical removal as well. Such an approach may have
the advantage of allowing cortex-sparing surgery, with less chance of
recurrence compared to cortex-sparing surgery in PCC, and may also
lead to a lower risk of developing bilateral PCC than thus far reported
[30]. Another advantage of early surgery for AMH is the fact that they
are often asymptomatic, which gives a lower chance for pre-operative
and intra-operative hypertensive crises.
In this study, we have shown that all MEN2-related AMH lesions,
nodular and/or diffuse, have genomic alterations identical to MEN2-
associated PCCs, at similar frequencies. Therefore, AMHs should be
regarded as PCC precursor lesions and not as non-neoplastic
hyperplasias. This is in line with other studies in which the value of
the size-based distinction between AMHs and PCCs has been
questioned and even considered as an academic difference rather than
a relevant clinical distinction [15,16,26].
As a consequence of these findings, we propose that the size
criterion for the distinction between AMH and PCC should be
abolished in patients with MEN2, and we recommend to replace the
term AMH by micro-PCC for nodular and/or diffuse adrenal
medullary lesions of less than 1 cm. In addition, treatment by cortex-
sparing adrenalectomy should be considered in case of a synchronous
or metachronous contralateral micro-PCC.
Figure 1. Left panel displays the LOH patterns of germ-line DNA (upper), PCC DNA (middle), and AMH DNA (lower) of case 14, for
chromosome 3q24. Loss is indicated by the arrow. Note that the PCC and AMH show different LOH patterns. Right panel shows the
sequences of a healthy control DNA (control) and the germ-line DNA, PCC DNA, and AMH DNA of case 9. Germ-line DNA displays the p.
Cys634Arg, TNC mutation in an equal ratio, whereas both PCC DNAs show a higher signal of the mutation (C) compared to the wild-type
signal (T), indicating amplification of the mutant allele.
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